📊 Expert Christiane Niederlaender advises companies to set quality attributes early and collect data throughout development.
🔑 Consistent analytics are crucial; discrepancies can derail product approvals.
👀 Ensure effective communication with regulators through a well-planned roadmap and targeted gap analysis.
Introduction:
The article discusses the critical role of analytics and data collection in achieving regulatory success for advanced therapy medicinal products (ATMPs). Insights from Christiane Niederlaender, an expert in chemistry, manufacturing, and controls at Parexel, underscore the importance of proper analytical techniques to ensure products meet regulatory standards in both the EU and the United States.
- Accurate comparability and analytical assays are essential for effective interactions with regulatory agencies regarding ATMPs.
- Inadequate analytical approaches can lead to unsuccessful product introductions, as illustrated by a case involving multiple FDA revisions due to unclear potency assay results.
- Continuity in analytical methods is crucial for maintaining comparability over time, emphasizing the importance of consistent testing parameters.
- Establishing quality attributes and specifications early in the development process allows for coherent potency assays that reflect the product’s mechanism of action.
- A structured roadmap for regulatory interactions, along with proper gap analyses of analytics, enables efficient communication with regulators and effective data collection strategies.
Conclusion:
The article emphasizes the necessity of establishing robust analytical processes and quality specifications early in the development of ATMPs. By adopting a methodological approach to data collection and regulatory interactions, companies can enhance their chances of compliance and success in the highly competitive biotechnology landscape. Future advancements in analytical techniques and regulatory frameworks will continue to shape the compliance landscape for biopharmaceutical innovations.
